Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In ...

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on ...

What Taysha Gene Therapies Stock Offers Investors Right Now Taysha Gene Therapies (TSHA) sits firmly in clinical-stage territory, working on adeno-associated virus-based gene therapies for severe ...

View Taysha Gene Therapies, Inc. TSHA stock quote prices, financial information, real-time forecasts, and company news from CNN.

14 analysts have expressed a variety of opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll ...

Astellas entered gene therapy development via a $3 billion acquisition. Another deal now positions it to potentially expand its gene therapy franchise further. Astellas is taking a minority stake in ...

Current pipeline of 15 AAV gene therapy programs with options to an additional 4 programs targeting severe and life-threatening monogenic CNS diseases in both rare and large-market indications Four ...

Shares of Taysha Gene Therapies ended at their highest level in over three years on Thursday after a wave of bullish analyst upgrades followed the U.S. Food and Drug Administration’s (FDA) ...

Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for ...

Tuesday, Taysha Gene Therapies Inc (NASDAQ:TSHA) shared initial clinical data from the first pediatric patient from the REVEAL Phase 1/2 adolescent and adult trial of TSHA-102, an investigational gene ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares are climbing after the company reported its fiscal year 2023 results after the bell Tuesday. Here's a look at the highlights. The Details: The company ...